Open Access

Expression, association with clinicopathological features and prognostic potential of CEP55, p‑Akt, FoxM1 and MMP‑2 in astrocytoma

  • Authors:
    • Saisai Nie
    • Lei Lou
    • Juan Wang
    • Jinfeng Cui
    • Wenxin Wu
    • Qing Zhang
    • Ying Liu
    • Lingrui Su
    • Ying Chang
    • Wenli Guo
    • Haitao Shen
    • Lingxiao Xing
    • Yuehong Li
  • View Affiliations

  • Published online on: June 17, 2020     https://doi.org/10.3892/ol.2020.11742
  • Pages: 1685-1694
  • Copyright: © Nie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Centrosomal protein 55 (CEP55) is a member of the centrosomal‑associated protein family and participates in the regulation of cytokinesis during cell mitosis. However, aberrant CEP55 protein expression has been observed in human tumors. In addition, CEP55 regulates the biological functions of tumors by inducing the Akt pathway and upregulating forkhead box protein M1 (FoxM1) and matrix metalloproteinase‑2 (MMP‑2). In the present study, the levels, clinicopathological features and prognostic potential of CEP55, phosphorylated Akt (p‑Akt), FoxM1 and MMP‑2 in astrocytoma were evaluated. CEP55, p‑Akt, FoxM1 and MMP‑2 levels were examined in 27 normal brain tissues and 262 astrocytoma tissues by using immunohistochemistry. Furthermore, Kaplan‑Meier analysis and Cox proportional hazards models were applied to predict the prognosis of patients with astrocytoma. The results indicated that expression levels of CEP55 and other proteins were elevated in human astrocytoma compared with those in normal brain tissue. The levels of the selected proteins were increased as the tumor grade increased. Furthermore, CEP55 expression was positively correlated with p‑Akt, FoxM1 and MMP‑2 levels in astrocytoma. Overall survival analysis revealed that patient prognosis was associated with CEP55, p‑Akt, FoxM1 and MMP‑2 levels, as well as with the tumor grade and patient age. Furthermore, CEP55, FoxM1, tumor grade and patient age were independent prognostic factors in astrocytoma according to multivariate analysis. Taken together, the present results suggested that CEP55, p‑Akt, FoxM1 and MMP‑2 have crucial roles in the progression and prognosis of human astrocytoma and that CEP55 and FoxM1 may be potential therapeutic targets.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Nie, S., Lou, L., Wang, J., Cui, J., Wu, W., Zhang, Q. ... Li, Y. (2020). Expression, association with clinicopathological features and prognostic potential of CEP55, p‑Akt, FoxM1 and MMP‑2 in astrocytoma. Oncology Letters, 20, 1685-1694. https://doi.org/10.3892/ol.2020.11742
MLA
Nie, S., Lou, L., Wang, J., Cui, J., Wu, W., Zhang, Q., Liu, Y., Su, L., Chang, Y., Guo, W., Shen, H., Xing, L., Li, Y."Expression, association with clinicopathological features and prognostic potential of CEP55, p‑Akt, FoxM1 and MMP‑2 in astrocytoma". Oncology Letters 20.2 (2020): 1685-1694.
Chicago
Nie, S., Lou, L., Wang, J., Cui, J., Wu, W., Zhang, Q., Liu, Y., Su, L., Chang, Y., Guo, W., Shen, H., Xing, L., Li, Y."Expression, association with clinicopathological features and prognostic potential of CEP55, p‑Akt, FoxM1 and MMP‑2 in astrocytoma". Oncology Letters 20, no. 2 (2020): 1685-1694. https://doi.org/10.3892/ol.2020.11742